[Translation] BHV3000-310: Phase 3: Double-blind, randomized, placebo-controlled, safety and efficacy trial of 75 mg BHV-3000 (rimegepant) in the acute treatment of migraine
通过测量给药后2小时的疼痛消除作用和对最困扰的偏头痛有关症状(MBS)的消除作用这一共同主要终点来评估Rimegepant相比安慰剂在偏头痛急性期治疗方面的有效性。
[Translation] The efficacy of rimegepant compared with placebo in the acute treatment of migraine was assessed by measuring the co-primary endpoints of pain freedom 2 hours after dosing and freedom from the most bothersome migraine-related symptom (MBS).